Phio Pharmaceuticals Corp (PHIO)

[Inoviorulez]

Another Collaboration agreement using Rxi's sd-rxRNA platform. I keep telling people that the tech works its just for scarring the doses need to be adjusted is all.

Lysaker, 7 April 2015 – PCI Biotech (OSE: PCIB), a Norwegian cancer focused biopharmaceutical company, today announced that it is initiating a pre-clinical research collaboration with RXi Pharmaceuticals (NASDAQ: RXII), an American biotechnology company focused on discovering and developing innovative therapeutics, that address high-unmet medical needs primarily in the area of dermatology and ophthalmology. The partnership is governed by a pre-clinical research collaboration agreement.

Initially, the purpose of the pre-clinical research collaboration is to utilize the companies’ complementary scientific platforms to explore potential synergies.

In brief the pre-clinical research collaboration will evaluate technology compatibility based on in vitro and in vivo studies. The costs related to the research collaboration will be covered by each company separately. The companies will evaluate results achieved from this research collaboration and then explore the potential for a closer collaboration.

Both companies will retain exclusive ownership rights to existing registered intellectual property. However, any inventions arising from the collaboration will be jointly owned by the companies.